<SEC-DOCUMENT>0001157523-18-000022.txt : 20180104
<SEC-HEADER>0001157523-18-000022.hdr.sgml : 20180104
<ACCEPTANCE-DATETIME>20180104164528
ACCESSION NUMBER:		0001157523-18-000022
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20180104
FILED AS OF DATE:		20180104
DATE AS OF CHANGE:		20180104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		18510681

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a51738215.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2018 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <br>
      <font style="font-family: Times New Roman; font-size: 16pt"><b>UNITED
      STATES</b></font><b><font style="font-family: Times New Roman; font-size: 16pt"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-family: Times New Roman; font-size: 16pt">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-family: Times New Roman; font-size: 10pt"><b>Washington,
      D.C. 20549</b></font>
    </p>
    <hr style="color: #000000; text-align: center; width: 100%; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 14pt"><b>FORM 6-K</b></font>
    </p>
    <hr style="color: #000000; text-align: center; width: 100%; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-family: Times New Roman"><b>&#160;</b></font><b><font style="font-family: Times New Roman; font-size: 12pt">REPORT
      OF FOREIGN PRIVATE ISSUER</font></b><br><font style="font-family: Times New Roman; font-size: 12pt"><b>PURSUANT
      TO RULE 13A-16 OR 15D-16 UNDER THE</b></font><br><font style="font-family: Times New Roman; font-size: 12pt"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br><br><font style="font-family: Times New Roman; font-size: 10pt"><b>Dated</b></font><font style="font-family: Times New Roman; font-size: 10pt">
      </font><font style="font-family: Times New Roman; font-size: 10pt"><b>January
      4, 2018</b></font><br><br><font style="font-family: Times New Roman; font-size: 10pt"><b>Commission
      File Number</b></font><b> 001-36421</b>
    </p>
    <hr style="color: #000000; text-align: center; width: 100%; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-size: 24pt"><b>AURINIA PHARMACEUTICALS INC.</b></font><br><b>(Exact
      name of Registrant as specified in its charter)</b><br><br>
    </p>
    <hr style="color: #000000; text-align: center; width: 100%; height: 1.0 pt">


    <p style="text-align: center">
      <b>N/A</b><br><b>(Translation of Registrant&#8217;s Name)</b><br><br>
    </p>
    <p style="text-align: center">
      <b>#1203-4464 Markham Street</b><br><b>Victoria, British Columbia</b><br><b>V8Z7X8</b><br><b>(250)
      708-4272</b><br><b>(Address and telephone number of registrant&#8217;s
      principal executive offices)</b>
    </p>
    <p style="text-align: center">

    </p>
    <hr style="color: #000000; text-align: center; width: 100%; height: 1.0 pt">


    <p style="text-align: left; text-indent: 30.0px">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark whether the registrant files or will file annual reports
      under cover of Form 20-F or Form 40-F.</font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">Form 20-F &#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><font style="font-family: Times New Roman; font-size: 10pt">
      &#160;&#160;&#160;&#160;Form 40-F&#160; </font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8864;</font>
    </p>
    <p style="text-align: left; text-indent: 30.0px">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(1):&#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><br>
    </p>
    <p style="text-align: left; text-indent: 30.0px">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(7):&#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><br>
    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark whether by furnishing the information contained in this Form,
      the registrant is also thereby furnishing the information to the
      Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
      of 1934.</font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">Yes &#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8864;</font><font style="font-size: 12pt">&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman; font-size: 10pt">
      No &#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font>
    </p>
    <div style="margin-right: 0pt; width: 100%; text-indent: 0pt; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt">
      </font><font style="font-family: Times New Roman; font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 10pt; margin-bottom: 10.0px">
      <tr>
        <td style="text-align: left; width: 6%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Dated:
          </p>
        </td>
        <td style="text-align: left; width: 49%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            January 4, 2018
          </p>
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 49%">

        </td>
        <td style="text-align: left; padding-left: 0.0px" colspan="3" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 49%">

        </td>
        <td style="text-align: left; padding-left: 0.0px" colspan="3" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Aurinia Pharmaceuticals Inc.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 49%">

        </td>
        <td style="text-align: center; padding-left: 0.0px" colspan="3" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: left; width: 6%; padding-bottom: 2.0px; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: left; width: 49%; padding-bottom: 2.0px; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: left; width: 3%; padding-bottom: 2.0px; padding-left: 0.0px" valign="top">
          By:
        </td>
        <td style="border-bottom-width: 1.0pt; text-align: left; border-bottom-color: black; border-bottom-style: solid; padding-left: 0.0px" colspan="2" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Dennis Bourgeault
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 49%">

        </td>
        <td style="text-align: left; width: 3%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: left; width: 5%; padding-left: 0.0px" valign="top">
          Name:
        </td>
        <td style="text-align: left; width: 37%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Dennis Bourgeault
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: left; width: 6%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: left; width: 49%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td style="text-align: left; width: 5%; padding-left: 0.0px" valign="top">
          Title:
        </td>
        <td style="text-align: left; width: 37%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">

    </p>
    <div style="width: 100%; margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center; font-family: Times New Roman; font-size: 10pt">
          2
        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>EXHIBIT&#160;INDEX</b>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 10pt; margin-bottom: 10.0px">
      <tr>
        <td style="border-bottom-width: 1.0pt; text-align: left; width: 7%; border-bottom-color: black; border-bottom-style: solid; padding-left: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Exhibit</b>
          </p>
        </td>
        <td style="text-align: left; width: 5%; padding-bottom: 2.0px; padding-left: 0.0px" valign="bottom">
          &#160;
        </td>
        <td style="border-bottom-width: 1.0pt; text-align: left; width: 88%; border-bottom-color: black; border-bottom-style: solid; padding-left: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Description of Exhibit</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="text-align: left; width: 88%; padding-left: 0.0px" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; width: 7%; white-space: nowrap; padding-left: 0.0px; padding-right: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <a href="a51738215ex99_1.htm">99.1</a>
          </p>
        </td>
        <td style="width: 5%">

        </td>
        <td style="text-align: left; width: 88%; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <a href="a51738215ex99_1.htm">News Release - Aurinia
            Pharmaceuticals files New Preliminary Base Shelf Prospectus to
            Replace Expired Base Shelf Prospectus</a>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      3
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51738215ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2018 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>Aurinia
      Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace
      Expired Base Shelf Prospectus</b></font>
    </p>
    <p>
      VICTORIA, British Columbia--(BUSINESS WIRE)--January 4, 2018--Aurinia
      Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (&#8220;<b>Aurinia</b>&#8221;
      or the &#8220;<b>Company</b>&#8221;) today announced that in order to replace
      its prior expired base shelf prospectus and corresponding shelf
      registration statement it has filed a preliminary short form base shelf
      prospectus (the &#8220;<b>Preliminary Shelf Prospectus</b>&#8221;) with the
      securities commissions in each of the provinces of Ontario, Alberta and
      British Columbia in Canada, and a corresponding shelf registration
      statement on Form F-10 with the U.S. Securities and Exchange Commission
      (the &#8220;<b>SEC</b>&#8221;) under the U.S./Canada Multijurisdictional
      Disclosure System.
    </p>
    <p>
      The Preliminary Shelf Prospectus and corresponding shelf registration
      statement, when made final or effective, will allow Aurinia to offer up
      to US$250,000,000 of common shares, warrants, subscription receipts,
      debt securities or any combination thereof during the 25-month period
      that the Preliminary Shelf Prospectus is effective. The Company has no
      immediate intention to undertake an offering. However, the Preliminary
      Shelf Prospectus will enable Aurinia to potentially access new capital
      if and when needed. The amount and timing of any future offerings will
      be based on the Company&#8217;s financial requirements and market conditions
      at the time. In addition, the Preliminary Shelf Prospectus and
      corresponding shelf registration statement allows Aurinia to meet its
      contractual obligation to maintain a valid registration statement to
      certain holders of warrants issued under a private placement that took
      place in June 2016.
    </p>
    <p>
      The specific terms of any future offering under the Preliminary Shelf
      Prospectus will be established at the time of such offering. At the time
      any of the securities covered by the Preliminary Shelf Prospectus are
      offered for sale, a prospectus supplement containing specific
      information about the terms of such offering will be filed with
      applicable Canadian securities regulatory authorities and the SEC.
    </p>
    <p>
      The shelf registration statement filed today with the SEC has not yet
      become effective. No securities may be sold, nor may offers to buy be
      accepted, prior to the time the registration statement becomes
      effective. This news release shall not constitute an offer to sell or a
      solicitation of an offer to buy, nor shall there be any sale of these
      securities in any jurisdiction in which an offer, solicitation or sale
      would be unlawful prior to registration or qualifications under the
      securities laws of any such jurisdiction.
    </p>
    <p>
      A copy of the Preliminary Shelf Prospectus can be found on SEDAR at <u>www.sedar.com</u>
      and a copy of the corresponding shelf registration statement can be
      found on EDGAR at <u>www.sec.gov</u> or may be obtained upon request to
      Aurinia&#8217;s Investor Relations Department using the contact information
      set out below.
    </p>
    <p>
      <i><b>About Aurinia</b></i><br>Aurinia is a clinical stage
      biopharmaceutical company focused on developing and commercializing
      therapies to treat targeted patient populations that are suffering from
      serious diseases with a high unmet medical need. The company is
      currently developing voclosporin, an investigational drug, for the
      treatment of lupus nephritis, focal segmental glomerulosclerosis,
      minimal change disease and dry eye syndrome. The company is
      headquartered in Victoria, BC and focuses its development efforts
      globally.
    </p>
    <div style="margin-right: 0pt; width: 100%; text-indent: 0pt; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <i><b>Forward-Looking Statement Disclaimer</b></i><br>Certain of the
      statements made in this news release may contain forward-looking
      information within the meaning of applicable Canadian securities law and
      forward-looking statements within the meaning of applicable United
      States securities law. Forward-looking information or statements may not
      be based on historical fact, and may include without limitation
      statements containing the words &#8220;believe&#8221;, &#8220;may&#8221;, &#8220;plan&#8221;, &#8220;will&#8221;,
      &#8220;estimate&#8221;, &#8220;continue&#8221;, &#8220;anticipate&#8221;, &#8220;intend&#8221;, &#8220;expect&#8221; and similar
      expressions. Forward-looking statements in this news release include
      statements regarding the Preliminary Shelf Prospectus and corresponding
      shelf registration statement being cleared by the applicable securities
      regulatory authorities and Aurinia&#8217;s ability to take advantage of
      financing opportunities in favourable market conditions or at all. Such
      forward-looking statements involve known and unknown risks,
      uncertainties and other factors that may cause the actual results,
      events or developments to be materially different from any future
      results, events or developments expressed or implied by such
      forward-looking statements. Many such known risks, uncertainties and
      other factors are taken into account as part of the Company&#8217;s
      assumptions underlying these forward-looking statements and include,
      among others, the following: general economic and business conditions in
      the United States, Canada, Europe, and the other regions in which
      Aurinia operates; not receiving the regulatory approvals, including the
      further approvals that may be sought from securities regulatory
      authorities or the SEC, on the timelines required or at all, that the
      prevailing market price of the Company&#8217;s securities may make a
      prospectus offering in respect of such securities unattractive to
      Aurinia as well as those factors discussed in or referred to under the
      heading &#8220;Risk Factors&#8221; in Aurinia&#8217;s Annual Report on Form 40-F for the
      year ended December 31, 2016 which is available under Aurinia&#8217;s profile
      on SEDAR at <u>www.sedar.com</u> and on EDGAR at <u>www.sec.gov</u>.
      Given these risks, uncertainties and factors, you are cautioned not to
      place undue reliance on such forward-looking statements and information,
      which are qualified in their entirety by this cautionary statement. All
      forward-looking statements and information made herein are based on our
      current expectations and we undertake no obligation to revise or update
      such forward-looking statements and information to reflect subsequent
      events or circumstances, except as required by law.
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br><b>Aurinia Pharmaceuticals Inc.</b><br><b>Investors &amp; Media:</b><br>Celia
      Economides<br>Vice-President, Public Affairs<br><u>ceconomides@auriniapharma.com</u><br>or<br>Dennis
      Bourgeault<br>Chief Financial Officer<br><u>dbourgeault@auriniapharma.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
